Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (21)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hergesell, O.
Right arrow Articles by Ritz, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hergesell, O.
Right arrow Articles by Ritz, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2002) 17: 14-17
© 2002 European Renal Association-European Dialysis and Transplant Association

Editorial Comments

Phosphate binders in uraemia: pharmacodynamics, pharmacoeconomics, pharmacoethics

Olaf Hergesell and Eberhard Ritz

Department Internal Medicine, Heidelberg, Germany

Keywords: hyperphosphataemia; phosphate binders; uraemia

The consequences of hyperphosphataemia

In the past nephrologists were aware that the hyperphosphataemia of advanced renal failure triggered hyperparathyroidism, but because only few patients die from skeletal problems, hyperphosphataemia was treated with benign neglect. The panorama has abruptly changed after evidence accrued suggesting that hyperphosphataemia has adverse cardiovascular consequences. In some observational studies [1], but not consistently in all [2], pre-dialysis serum P concentrations >6.5 mg/dl were associated with a higher relative risk of cardiovascular death. Furthermore, with the availability of electronbeam-CT, a high prevalence of vascular, particularly coronary, calcification was noted in dialysed patients, which was progressive with time [3,4]. Furthermore, the group of London has shown that active wall stiffness is correlated to vascular calcification [5]. Vascular calcifications are presumably more than the result of passive precipitation of Ca and P, and under certain conditions vascular smooth muscle cells can even acquire, . . . [Full Text of this Article]

The phosphate balance

Classical P binders

Aluminium-containing phosphate binders
Calcium-containing P binders
Novel P binders

Sevelamer
Lanthanum
Polynuclear iron preparations
Points to consider when selecting P binders

Notes

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
G. B. Spasovski, A. Sikole, S. Gelev, J. Masin-Spasovska, T. Freemont, I. Webster, M. Gill, C. Jones, M. E. De Broe, and P. C. D'Haese
Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up
Nephrol. Dial. Transplant., August 1, 2006; 21(8): 2217 - 2224.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
T. B. Drueke and S. G. Rostand
Progression of vascular calcification in uraemic patients: can it be stopped?
Nephrol. Dial. Transplant., August 1, 2002; 17(8): 1365 - 1368.
[Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
D. Goldsmith, R. MacGinley, A. Smith, and A. Covic
How important and how treatable is vascular stiffness as a cardiovascular risk factor in renal failure?
Nephrol. Dial. Transplant., June 1, 2002; 17(6): 965 - 969.
[Full Text] [PDF]